

Rafael Elias Marques

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5721431/rafael-elias-marques-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

1,436
citations

19
h-index

37
g-index

51
ext. papers

1,982
ext. citations

7.2
avg, IF

4.27
L-index

#	Paper	IF	Citations
37	Structural dynamics of SARS-CoV-2 nucleocapsid protein induced by RNA binding.. <i>PLoS Computational Biology</i> , 2022 , 18, e1010121	5	3
36	Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	53
35	Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza. <i>JCI Insight</i> , 2021 ,	9.9	7
34	Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. <i>Nature Communications</i> , 2021 , 12, 6844	17.4	3
33	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021 , 13,	6.2	1
32	Flavonoids from <i>Pterogyne nitens</i> as Zika virus NS2B-NS3 protease inhibitors. <i>Bioorganic Chemistry</i> , 2021 , 109, 104719	5.1	8
31	Cryo-EM structure of the mature and infective Mayaro virus at 4.4 Å resolution reveals features of arthritogenic alphaviruses. <i>Nature Communications</i> , 2021 , 12, 3038	17.4	7
30	Serological Testing for COVID-19, Immunological Surveillance, and Exploration of Protective Antibodies. <i>Frontiers in Immunology</i> , 2021 , 12, 635701	8.4	3
29	Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. <i>Lancet Microbe, The</i> , 2021 , 2, e527-e535	22.2	38
28	Type I interferons are essential while type II interferon is dispensable for protection against St. Louis encephalitis virus infection in the mouse brain. <i>Virulence</i> , 2021 , 12, 244-259	4.7	1
27	Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1271	6.8	14
26	Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 α /Glycolysis-Dependent Axis. <i>Cell Metabolism</i> , 2020 , 32, 437-446.e5	24.6	268
25	A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. <i>MBio</i> , 2020 , 11,	7.8	13
24	Shielding and stealth effects of zwitterion moieties in double-functionalized silica nanoparticles. <i>Journal of Colloid and Interface Science</i> , 2019 , 553, 540-548	9.3	15
23	Biological and social challenges of human reproduction in a long-term Mars base. <i>Futures</i> , 2018 , 100, 56-62	3.6	25
22	Interleukin-33 contributes to disease severity in Dengue virus infection in mice. <i>Immunology</i> , 2018 , 155, 477-490	7.8	5
21	Zika-virus-infected human full-term placental explants display pro-inflammatory responses and undergo apoptosis. <i>Archives of Virology</i> , 2018 , 163, 2687-2699	2.6	14

20	Host target-based approaches against arboviral diseases. <i>Biological Chemistry</i> , 2018 , 399, 203-217	4.5	1
19	A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. <i>Npj Vaccines</i> , 2018 , 3, 56	9.5	27
18	Thiosemicarbazones and Phthalyl-Thiazoles compounds exert antiviral activity against yellow fever virus and Saint Louis encephalitis virus. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 87, 381-387	7.5	21
17	-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by Zika Virus Infection. <i>MBio</i> , 2017 , 8,	7.8	48
16	Development of a model of Saint Louis encephalitis infection and disease in mice. <i>Journal of Neuroinflammation</i> , 2017 , 14, 61	10.1	7
15	Hydrocephalus and arthrogryposis in an immunocompetent mouse model of ZIKA teratogeny: A developmental study. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005363	4.8	30
14	The Viral Polymerase Inhibitor 7-Deaza-2UC-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. <i>PLoS Neglected Tropical Diseases</i> , 2016 , 10, e0004695	4.8	213
13	Exploring the Homeostatic and Sensory Roles of the Immune System. <i>Frontiers in Immunology</i> , 2016 , 7, 125	8.4	22
12	Zika crisis in Brazil: challenges in research and development. <i>Current Opinion in Virology</i> , 2016 , 18, 76-81	7.5	24
11	First genome sequence of St. Louis encephalitis virus (SLEV) isolated from a human in Brazil. <i>Archives of Virology</i> , 2015 , 160, 1189-95	2.6	8
10	Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. <i>Immunology</i> , 2015 , 145, 583-96	7.8	39
9	Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. <i>Hepatology</i> , 2015 , 61, 348-60	11.2	102
8	Targeting CCL5 in inflammation. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 1439-60	6.4	141
7	IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection. <i>European Journal of Immunology</i> , 2013 , 43, 1529-44	6.1	42
6	Isolation of saint louis encephalitis virus from a horse with neurological disease in Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2013 , 7, e2537	4.8	28
5	A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection. <i>American Journal of Pathology</i> , 2011 , 179, 1872-83	5.8	29
4	Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice. <i>PLoS ONE</i> , 2010 , 5, e15680	3.7	48
3	SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes		15

2	Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial	5
1	Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination. <i>SSRN Electronic Journal</i> ,	1 17